Four Companies In Japan Launch G-CSF Biosimilars
This article was originally published in PharmAsia News
Mochida, Fuji Seiyaku Kogyo, Nippon Kayaku, and Teva all announced the launch of their G-CSF biosimilars of Kyowa Hakko Kirin’s filgrastim after the drugs were put on the NHI price listing.
You may also be interested in...
France has announced a number of emergency measures to protect drug supplies threatened by the spread of the coronavirus.
Major generics companies have donated hydroxychloroquine sulfate doses for research and treatment of coronavirus. Companies are also donating hand sanitizer and personal protective equipment and are preparing to ramp up manufacturing and production.
Inovio forges ahead into Phase I trials with DNA-based vaccine candidate, but can it prove skeptics wrong?